| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
ALX Oncology Holdings Inc (NASDAQ: ALXO)
ALXO Technical Analysis
5
| As on 9th Jun 2023 ALXO STOCK Price closed @ 8.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 13.40 & Strong Sell for SHORT-TERM with Stoploss of 17.83 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ALXOSTOCK Price
| Open | 8.00 | Change | Price | % |
| High | 8.16 | 1 Day | 0.06 | 0.76 |
| Low | 7.86 | 1 Week | 1.19 | 17.47 |
| Close | 8.00 | 1 Month | 2.51 | 45.72 |
| Volume | 174000 | 1 Year | -15.89 | -66.51 |
| 52 Week High 23.89 | 52 Week Low 4.37 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ALXO Daily Charts |
ALXO Intraday Charts |
Whats New @ Bazaartrend |
ALXO Free Analysis |
|
|
ALXO Important Levels Intraday
| RESISTANCE | 8.58 |
| RESISTANCE | 8.39 |
| RESISTANCE | 8.28 |
| RESISTANCE | 8.16 |
| SUPPORT | 7.84 |
| SUPPORT | 7.72 |
| SUPPORT | 7.61 |
| SUPPORT | 7.42 |
ALXO Forecast May 2024
| 4th UP Forecast | 25.07 |
| 3rd UP Forecast | 19.6 |
| 2nd UP Forecast | 16.21 |
| 1st UP Forecast | 12.83 |
| 1st DOWN Forecast | 3.17 |
| 2nd DOWN Forecast | -0.21 |
| 3rd DOWN Forecast | -3.6 |
| 4th DOWN Forecast | -9.07 |
ALXO Weekly Forecast
| 4th UP Forecast | 14.69 |
| 3rd UP Forecast | 12.54 |
| 2nd UP Forecast | 11.22 |
| 1st UP Forecast | 9.89 |
| 1st DOWN Forecast | 6.11 |
| 2nd DOWN Forecast | 4.78 |
| 3rd DOWN Forecast | 3.46 |
| 4th DOWN Forecast | 1.31 |
ALXO Forecast2024
| 4th UP Forecast | 45.67 |
| 3rd UP Forecast | 33.59 |
| 2nd UP Forecast | 26.12 |
| 1st UP Forecast | 18.65 |
| 1st DOWN Forecast | -2.65 |
| 2nd DOWN Forecast | -10.12 |
| 3rd DOWN Forecast | -17.59 |
| 4th DOWN Forecast | -29.67 |
ALX Oncology Holdings Inc ( NASDAQ USA Symbol : ALXO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ALXO Business Profile
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California. Address: 866 Malcolm Road, Burlingame, CA, United States, 94010
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service